Abstract
Background and aims Heart Failure with Preserved Ejection Fraction (HFpEF) accounts for approximately half of all heart failure cases, with high levels of morbidity and mortality. However, most cases of HFpEF are undiagnosed as conventional risk scores underestimate risk in non-White populations. Our aim was to develop and validate a diagnostic prediction model to detect undiagnosed HFpEF, AIM-HFpEF.
Methods We applied natural language processing (NLP) and machine learning methods to routinely collected electronic health record (EHR) data from a tertiary centre hospital trust in London, UK, to derive the AIM-HFpEF model. We then externally validated the model and performed benchmarking against existing HFpEF prediction models (H2FPEF and HFpEF-ABA) for diagnostic power in patients of non-white ethnicity and patients from areas of increased socioeconomic deprivation.
Results An XGBoost model combining demographic, clinical and echocardiogram data showed strong diagnostic performance in the derivation dataset (n=3170, AUC=0.88, [95% CI, 0.86-0.91]) and validation cohort (n=5383, AUC: 0.88 [95% CI, 0.87-0.89]). Diagnostic performance was maintained in patients of non-White ethnicity (AUC=0.88 [95% CI, 0.84-0.93]) and patients from areas of high socioeconomic deprivation (AUC=0.89 [95% CI, 0.84-0.94]). and AIM-HFpEF performed favourably in comparison to H2FPEF and HFpEF-ABA models. AIM-HFpEF model probabilities were associated with an increased risk of death, hospitalisation and stroke in the external validation cohort (P<0.001, P=0.01, P<0.001 respectively for highest versus middle tertile).
Conclusion AIM-HFpEF represents a validated equitable diagnostic model for HFpEF, which can be embedded within an EHR to allow for fully automated HFpEF detection.
Competing Interest Statement
TAM has received speaker's fees and advisory board fees from Abbott, Edwards, Boehringer Ingelheim, and AstraZeneca. AMS serves as an advisor to Forcefield Therapeutics and CYTE- Global Network for Clinical Research. All other authors have nothing to disclose. TFL does not accept any honoraria from industry, but has received research and educational grants from Abbott, Amgen AstraZeneca, Boehringer Ingelheim, Daich-Sankyo, Eliy Lilly, Novartis, Novo Nordisk, Sanofi and Vifor.
Funding Statement
This work was supported by the Adrian Beecroft British Heart Foundation Cardiovascular Catalyst Award (CC/22/250022 to AMS, KOG, RJD and JT) with further support from the British Heart Foundation (CH/1999001/11735, RG/20/3/34823 and RE/18/2/34213 to AMS) and King's College Hospital Charity (D/3003/122022/Shah/1188 to AMS). KOG and DIB are each supported by MRC Clinician Scientist Fellowships (MR/Y001311/1 to KOG, MR/X001881/1 to DB).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This project operated under London South-East Research Ethics Committee approval (18/LO/2048) granted to the King's Electronic Records Research Interface (KERRI) and London Dulwich Research Ethics Committee approval (19/LO/1957), which did not require written informed patient consent. The study complies with the Declaration of Helsinki. Patients were consulted on the study via a dedicated patient and public involvement (PPI) meeting held during the study design phase. A formal protocol was not published and the study was not registered.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
The data and code underlying this article will be shared on reasonable request to the corresponding author.
